Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Inhibikase Therapeutics Inc
IKTCurrent price
2.37 USD
0 USD (0.00%)
Last closed
2.37 USD
Company
www.inhibikase.com
ISIN
US45719W1062
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
239 877 584 USD
Yield for 12 month
+7.24 %
1Y
3Y
5Y
10Y
15Y
IKT
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Address: 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7.00 USDP/E ratio
–Dividend Yield
–Current Year
+260 500 USD
Last Year
+123 440 USD
Current Quarter
–
Last Quarter
–
Current Year
-13 357 848 USD
Last Year
+116 717 USD
Current Quarter
–
Last Quarter
-6 569 USD
Key Figures IKT
1 year
3 years
5 years
10 years
EBITDA
-18 979 048 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-76.21 %
PEG Ratio
–
Return On Equity TTM
-149.69 %
Wall Street Target Price
7.00 USD
Revenue TTM
79 570 USD
Book Value
1.78 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
-8 258 499 USD
Earnings per share
-3.12 USD
Diluted Eps TTM
-3.12 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics IKT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History IKT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
30.06.2023
Stock Valuation IKT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
2.75
Price Sales TTM
3 014.67
Enterprise Value EBITDA
0.34
Price Book MRQ
26.46
Financials IKT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators IKT
For 52 weeks
1.12 USD
4.14 USD
50 Day MA
2.40 USD
Shares Short Prior Month
305 663
200 Day MA
1.81 USD
Short Ratio
0.17
Shares Short
287 662
Short Percent
0.29 %
BeatStart